117 related articles for article (PubMed ID: 20738358)
1. Apoptosis and cell proliferation correlated with tumour grade in peritoneal fluids of patients with serous ovarian cancer.
Kalogeraki A; Karvela-Kalogeraki I; Petraki PE; Zois I; Tamiolakis D; Stathopoulos EN
Cytopathology; 2011 Dec; 22(6):383-6. PubMed ID: 20738358
[TBL] [Abstract][Full Text] [Related]
2. DNA fragmentation and cell proliferation correlated with tumor grade in patients with hepatocellular carcinoma.
Kalogeraki A; Garbagnati F; Santinami M; Zoras O
Cancer; 2002 Oct; 96(5):301-5. PubMed ID: 12378598
[TBL] [Abstract][Full Text] [Related]
3. Apoptotic bodies as a morphological feature in serous ovarian carcinoma: correlation with nuclear grade, Ki-67 and mitotic indices.
Brustmann H
Pathol Res Pract; 2002; 198(2):85-90. PubMed ID: 11928869
[TBL] [Abstract][Full Text] [Related]
4. [Preliminary study on the relationship between tubal intraepithelial carcinoma of the fimbria and pelvic high-grade serous carcinoma].
Liang Y; Chen XD; Lü BJ; Zhou CY; Zhang XF; Shi HY
Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):724-8. PubMed ID: 22321343
[TBL] [Abstract][Full Text] [Related]
5. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
McCluggage WG
Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
[TBL] [Abstract][Full Text] [Related]
6. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
7. DNA fragmentation factor (DFF45): expression and prognostic value in serous ovarian cancer.
Brustmann H
Pathol Res Pract; 2006; 202(10):713-20. PubMed ID: 16962250
[TBL] [Abstract][Full Text] [Related]
8. THE PROGNOSTIC SIGNIFICANCE OF P53, BCL2 AND MIB1 EXPRESSIONS RELATED WITH OTHER CLINICOPATHOLOGICAL VARIABLES IN SEROUS OVARIAN CARCINOMAS. A CLINICOPATHOLOGICAL STUDY IN PERITONEAL FLUIDS.
Kalogeraki A; Tamiolakis D; Matalliotaki C; Karvela-Kalogeraki I; Karvelas-Kalogerakis M; Segredakis J; Sinatkas V; Matalliotakis I
Rev Med Chir Soc Med Nat Iasi; 2015; 119(2):454-60. PubMed ID: 26204652
[TBL] [Abstract][Full Text] [Related]
9. [Significance and mechanisms of overexpression of PAK1 gene in epithelial ovarian neoplasms].
Xie D; Yang GF; Chen YQ; Jiang LF; Xiao LZ
Zhonghua Zhong Liu Za Zhi; 2006 Dec; 28(12):911-4. PubMed ID: 17533742
[TBL] [Abstract][Full Text] [Related]
10. Integrin-linked kinase expression increases with ovarian tumour grade and is sustained by peritoneal tumour fluid.
Ahmed N; Riley C; Oliva K; Stutt E; Rice GE; Quinn MA
J Pathol; 2003 Oct; 201(2):229-37. PubMed ID: 14517840
[TBL] [Abstract][Full Text] [Related]
11. Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data.
Vang R; Shih IeM; Salani R; Sugar E; Ayhan A; Kurman RJ
Am J Surg Pathol; 2008 Nov; 32(11):1667-74. PubMed ID: 18769340
[TBL] [Abstract][Full Text] [Related]
12. Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome.
Brustmann H
Int J Gynecol Pathol; 2007 Apr; 26(2):147-53. PubMed ID: 17413981
[TBL] [Abstract][Full Text] [Related]
13. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM
Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of fascin expression in advanced poorly differentiated serous ovarian cancer.
Daponte A; Kostopoulou E; Papandreou CN; Daliani DD; Minas M; Koukoulis G; Messinis IE
Anticancer Res; 2008; 28(3B):1905-10. PubMed ID: 18630479
[TBL] [Abstract][Full Text] [Related]
15. Expression of cyclooxygenase-2 in advanced stage ovarian serous carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, and survival.
Ali-Fehmi R; Morris RT; Bandyopadhyay S; Che M; Schimp V; Malone JM; Munkarah AR
Am J Obstet Gynecol; 2005 Mar; 192(3):819-25. PubMed ID: 15746677
[TBL] [Abstract][Full Text] [Related]
16. [Clinicopathologic study and immunohistochemistry comparison of Pax2, p53 and Ki-67 in low- and high-grade ovarian serous carcinomas].
Shen XX; Yu L; Bi R; Yang WT
Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):511-6. PubMed ID: 22169637
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
[TBL] [Abstract][Full Text] [Related]
18. Expression of HER2/neu, estrogen and progesterone receptors, CA 125 and CA19-9 on cancer cell membrane in patients with serous and mucinous carcinoma of the ovary.
Karaferic A; Jovanovic D; Jelic S
J BUON; 2009; 14(4):635-9. PubMed ID: 20148455
[TBL] [Abstract][Full Text] [Related]
19. Tumour growth fraction and apoptosis in salivary gland acinic cell carcinomas. Prognostic implications of Ki-67 and bcl-2 expression and of in situ end labelling (TUNEL).
Hellquist HB; Sundelin K; Di Bacco A; Tytor M; Manzotti M; Viale G
J Pathol; 1997 Mar; 181(3):323-9. PubMed ID: 9155720
[TBL] [Abstract][Full Text] [Related]
20. Expression and prognostic significance of the oncogenic K2P potassium channel KCNK9 (TASK-3) in ovarian carcinoma.
Innamaa A; Jackson L; Asher V; Van Shalkwyk G; Warren A; Hay D; Bali A; Sowter H; Khan R
Anticancer Res; 2013 Apr; 33(4):1401-8. PubMed ID: 23564779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
